REPROCELL Corporate News
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE projects, by the Hartree National Centre for Digital Innovation (HNCDI), via a partnership between the Science and Technology Facilities Council (STFC) Hartree Centre and IBM. Through EXCELERATE, REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.
1 June 2023 • Drug Discovery
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
Yokohama Japan, 24 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for the treatment of spinocerebellar ataxia, as follows.
25 May 2023 • Stem Cells
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
Yokohama Japan, 24 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
23 May 2023 • Stem Cells
End of Q4 update from REPROCELL (2022-23)
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO we have included a link below - plus everything else we’ve been up to since the start of 2023.
4 May 2023 • Life Sciences
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
REPROCELL USA, a CRO, has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”. The Harmonic™ study is being conducted to determine clinical advantages for Lantern Pharma’s investigational new drug LP-300 in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs).
3 May 2023 • Clinical Capabilities
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chika Yokoyama
On February 26, 2023, REPROCELL celebrated its 20th anniversary.
28 February 2023 • Life Sciences
End of Q3 update from REPROCELL (2022-23)
The year might be coming to a close, but we’re not winding down at REPROCELL. The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This includes our membership to the CIRM Industry Resource Partner Program and our latest agreement with the CDMO BioBridge global – both of which will make REPROCELL’s clinical iPSC technology and subsequent cell therapy manufacturing more accessible.
12 December 2022 • Life Sciences
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
Silo Pharma, Inc. has announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. Conducted in partnership with REPROCELL, this three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue. Initial data from the study is expected during the first quarter of 2023.
9 December 2022 • Drug Discovery
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
Yokohama Japan, 23 November 2022: REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
23 November 2022 • Stem Cells
Building economic resilience and unleashing productivity through digital innovation
UK enterprises are facing a number of disruptive forces that necessitate transformation at pace – macro-economic challenges, socio-political challenges, and the focus on our own resilience. Industries from across the country are in the grip of a far-ranging digital revolution; an accelerated transformation that’s being driven by the desire to innovate and an appetite for enhanced competitiveness.
9 November 2022 • Drug Discovery
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
Yokohama, Japan, 13 October 2022: REPROCELL Inc. and JTB Corp. will begin marketing "Personal iPS" (REPROCELL's iPSC storage and production service) overseas through the Japan Medical & Health Tourism Center (JMHC): a medical coordination division established by JTB.
13 October 2022 • Clinical Capabilities
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
Yokohama Japan, 5 October 2022: REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to make accessible REPROCELL’s unique induced Pluripotent Stem Cells (iPSCs) technology to CIRM Awardees.
5 October 2022 • Clinical Capabilities
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
YOKOHAMA, Japan: REPROCELL Inc. and San Antonio, Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship.
4 October 2022 • Clinical Capabilities
End of Q2 update from REPROCELL (2022-23)
We're halfway through the financial year and there are only three months left in 2022. Time is racing but REPROCELL has managed to pack in a lot since our last update, including three conferences and the launch of our clinical laboratory services in Europe. Here is a list of everything else we've been up to since the start of July:
3 October 2022 • Life Sciences
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning.
31 August 2022 • Drug Discovery
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to treat respiratory disease by assessing the effects of the drug ex vivo in human living bronchi.
17 August 2022 • Drug Discovery
Life science after lockdown - SPS returns for 2022
Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in safety pharmacology.
15 August 2022 • Drug Discovery
Bioserve India granted NABL accreditation in the field of Genomics Testing
Hyderabad, India - 9 August 2022: We are pleased to announce that Bioserve Biotechnologies India Pvt Ltd, a subsidiary of REPROCELL Inc, has received NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation for Medical Testing in the field of Genomics Testing Services. The accreditation is in accordance with ISO 15189: 2012 “Medical laboratories - Requirements for quality and competence”.
9 August 2022 • Clinical Capabilities
REPROCELL is On the Road at ISSCR 2022
This June, REPROCELL’s experts will be busy. We will be joining with stem cell scientists at ISSCR 2022 to allow scientists an opportunity to meet in person with REPROCELL’s experts at Booth 310 and discuss how we can help solve complex problems in Drug Discovery and Regenerative Medicine.
7 June 2022 • Stem Cells
Completion of Clinical Phase II Trials of Stemchymal in Japan
Yokohama Japan, 16 May 2022: We are pleased to announce that the Clinical Phase II Trial of Stemchymal, a regenerative medicine product derived from somatic stem cells, has been completed in Japan. Previously, on 24 May 2021, we announced that administrations of Stemchymal had been completed for all patients enrolled for the treatment of spinocerebellar ataxia. After data collection, we will unblind the allocation information for the blinded treatment/placebo group (i.e., code-break), conduct data analysis and evaluation, and prepare for submission for approval.
16 May 2022 • Clinical Capabilities
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies.
8 March 2022 • Drug Discovery
REPROCELL spotlights the power of smarter biospecimens in new global publication
Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled Dynamizing Biomarker R&D with Smarter Biospecimens, explains why quality biospecimens are essential to translational biomarker research.
21 January 2022 • Drug Discovery
REPROCELL signs agency agreement with Ajinomoto Group for the marketing and sales of StemFit Basic03 GMP
Yokohama Japan, 8 November 2021: REPROCELL has signed a new agency agreement with Ajinomoto Group for the marketing and sale of StemFit Basic03 GMP and GMP compliant recombinant human bFGF. These clinical-grade products are suitable for cell culture workflows leading to therapeutic applications.
8 November 2021 • Clinical Capabilities
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery.
25 October 2021 • Drug Discovery
Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine
Hyderabad India – 15 September 2021: Bioserve Biotechnologies India Pvt. Ltd. (a 100% owned subsidiary of REPROCELL Inc) will sponsor a webinar series hosted by the Society of Fetal Medicine in September. The title of the webinar is “Genetic Testing in Fetal Medicine-Navigating the Maze”.
15 September 2021
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company SOPARBIOTECH INTERNATIONAL.
2 September 2021 • Clinical Capabilities
REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing
Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company Soparbiotech International.
18 August 2021
REPROCELL highlights the power of human fresh tissue in global publication
Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).
5 July 2021 • Drug Discovery
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs).
29 June 2021 • Clinical Capabilities
REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant
Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian variants. These have all been identified as Variants of Concern (VOC) by the World Health Organization.
21 June 2021
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial for the treatment of spinocerebellar ataxia in Japan. The safety and efficacy of Stemchymal will continue to be investigated during a certain observation period.
24 May 2021 • Clinical Capabilities
VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
18 May 2021 • Clinical Capabilities
REPROCELL will participate at the Biotechgate Digital Partnering Event.
REPROCELL USA and REPROCELL Europe will be attending all 5 days of the Biotechgate Digital Partnering 2021 Event, 3-7 May 2021.
Partnering scheduling is now open, and registration is free.
Have a one-on-one Zoom meeting with our experts and get to know our capabilities of life sciences.
We may be a good partner for you in your research projects! We have included an overview of our available services below:
21 April 2021 • Life Sciences
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
Hyderabad India – 19 April 2021: Bioserve Biotechnologies India Pvt Ltd, a 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of clinical oncology diagnostic service in India. This new service is clinician-friendly, aiming to deliver comprehensive, NGS-based genomic profiling in oncology targeting a wide range of cancers. The company also provides pharmacogenomics testing using single gene panels, offering researchers detailed interpretations and recommendations that provide powerful insights for the development of targeted therapies.
19 April 2021 • Clinical Capabilities
Launch of New Testing Service of Identification for Covid-19 Variants
We are pleased to announce that on Tuesday 6th April 2021, REPROCELL launched a new testing service for the identification for Covid-19 variants using the Allplex SARS-CoV-2 Variants I Assay (referred to below as Allplex) manufactured by Seegene Inc. (South Korea). This will be offered in addition to full screening test for Covid-19 using cutting-edge SmartAmp technology that REPROCELL launched on March 1st 2021.
8 April 2021 • Clinical Capabilities
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
YOKOHAMA, 22 March, 2021/ REPROCELL has initiated a collaboration with Blacktrace Holdings Ltd in the sales of their Nadia series: a single-cell analytical system, in Japan.
22 March 2021 • Clinical Capabilities
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
YOKOHAMA, March 16, 2021/ We are pleased to announce that our cell processing facility, REPROCELL Regenerative Medicine Center (located in Life Innovation Center in the Kanagawa region), was certified as manufacturing facility for cell culture products (registration number: FA3200006) on March 8th, 2021 by Kanto-Shinetsu Regional Bureau of Health and Welfare.
17 March 2021 • Clinical Capabilities
Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL.
15 March 2021 • Drug Discovery
Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India
Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in India.
11 March 2021 • Clinical Capabilities
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
[Glasgow, UK] REPROCELL has contributed to a novel publication detailing advancements in induced pluripotent stem cell (iPSC) reprogramming. The paper, published in New Biotechnology by Dr Amer Rana and his team of researchers from the University of Cambridge, was in collaboration with Dr Sarah Eminli-Meissner, Head of Business for Stem Cell Research at REPROCELL. It describes techniques for reprogramming blood-derived cells endothelial progenitor cells, or “EPCs”, into iPSCs.
1 March 2021 • Stem Cells
REPROCELL launches PCR Testing Service for COVID-19
[Yokohama, Japan] REPROCELL will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc: a Japanese start-up company based on cutting-edge technologies developed by RIKEN, Japan’s largest comprehensive research institute.
1 March 2021 • Clinical Capabilities
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
All patients have been registered at ten sites in Japan for the Phase II clinical trial of Stemchymal®, a human adipose-derived stem cell product exclusively licensed in Japan by Steminent Biotherapeutics Inc. (hereinafter referred to as Steminent), where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with spinocerebellar ataxia (SCA).
25 February 2021 • Clinical Capabilities
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
[Hyderabad, India] Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced Bioserve Biotechnologies Pvt Ltd (REPROCELL’s 100% owned subsidiary) as the new distributor of its Maestro systems and consumables in India.
16 February 2021 • Stem Cells
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from January 2021 in Japan. REPROCELL has also launched a new B2C website to promote the Personal iPS service, which is currently only available in Japan.
17 December 2020 • Clinical Capabilities
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
Beltsville, USA: REPROCELL, an industry leader in the use of human biospecimens for medical research, has partnered with Scientist.com, the healthcare industry’s leading marketplace for life science research, to bring its services to the global biotechnology community. REPROCELL joins a select group of highly-rated marketplace VIP suppliers that commit to outstanding customer service and offer a discount to biotech customers.
10 December 2020
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
17 August 2020 • Clinical Capabilities
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
Yokahoma, Japan: REPROCELL announce the launch of StemRNA™ Entero: human iPSC-derived intestinal epithelial cells.
StemRNA™ Entero cells are intestinal epithelial cells derived from human iPSCs. This model was developed using advanced technologies established by Professor Shoen Kume (The Tokyo Institute of Technology) and REPROCELL, Inc. StemRNA™ Entero cells closely mimic the gene expression of intestinal epithelial cells; for example, they express high levels of the CYP3A4 gene – a key enzyme for metabolism – compared to Caco2 cells, an intestinal model system widely used to measure the absorption and metabolism of novel therapeutics. StemRNA™ Entero cells are designed for use as a more clinically relevant alternative to Caco2 cells in drug development.
15 July 2020 • Stem Cells
REPROCELL’s Personal iPS Service is Launched in Japan
Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) re established for future regenerative medicine treatment.
15 July 2020 • Clinical Capabilities
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
REPROCELL has recently joined an international consortium, led by Belgium company etheRNA, to develop a novel mRNA vaccine against CoV-2. Administered intranasally, the proposed vaccine is intended primarily for high risk populations such as healthcare workers and families of confirmed cases. It is designed to be protective against future variations of the virus by targeting conserved epitopes from the whole CoV-2 genome. In this article, REPROCELL (Biopta) CEO, Dr David Bunton, explains what separates this vaccine from other candidates in development.
13 July 2020 • Drug Discovery
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal®.
28 February 2020 • Clinical Capabilities
Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
Dates: 19-20 February 2020
Venue: Copthorne Tara, London, United Kingdom
REPROCELL Europe’s CSO Professor Stefan Przyborski will giving the keynote address on 3D cell culture at this year’s SMi 4th Annual Conference London, UK. There Prof Przyborski will also be showcasing REPROCELL’s range of Alvetex products for 3D cell culture.
13 February 2020
Patients with IBD absorb drugs differently from healthy individuals
A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patient group. A similar study, performed by Keio University, estimated drug absorption in healthy areas of GI tissue from ulcerative colitis (UC) donors.
16 January 2020
REPROCELL can now predict oral bioavailability in fresh IBD tissue
Glasgow, UK: REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal (GI) resections from Inflammatory Bowel Disease (IBD) donors. This service, which is first of its kind to market, will allow ADME/DMPK scientists to estimate compound permeability in living human IBD tissue.
14 January 2020
Early understanding of pharmacology and genomics can improve precision medicine strategies
Glasgow, UK: REPROCELL (Biopta) today announced the successful publication of a novel study in pharmacology and genomics to improve strategies for the development of precision medicines. The study – performed in collaboration with the NHS, academia and Scottish companies Fios Genomics, Systemic, and Aridhia – used human living lung tissue from Chronic Obstructive Pulmonary Disease (COPD) donors to explain inter-patient variation in drug efficacy.
23 December 2019
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
Lantern Pharma a clinical stage oncology biotech leveraging A.I. and machine learning genomics company has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.
13 November 2019
Appointment of New Distributor in Thailand
The REPROCELL group has signed a non-exclusive distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand.
4 November 2019
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF).
25 October 2019
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
Yokohama, Japan, & San Carlos, California, USA — REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship.
Although NeuCyte has direct sales in North America, this new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements. These components come in kit formats so the user can set up well-defined, highly functional in vitro co-culture systems for compound screening, disease modeling and neurotoxicity assessment.
25 September 2019
PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor
Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.
28 August 2019
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
The lab-scale system will allow researchers to study and culture stem cells in suspension
Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.
“We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.
22 August 2019
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders. The suite has been designed to support Clinical Trials of cell therapy products.
13 May 2019
REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy
24 April 2019
How the Medical Discovery Catapult is Improving Precision Medicine
The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.
28 March 2019
UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
14 March 2019
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
- The collaboration is part of Medicines Discovery Catapult’s Virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour.
- The collaboration is part of Medicines Discovery Catapult’s Virtual R&D network, which aims to support UK SMEs develop and execute their drug discovery projects with industrial rigour
Glasgow UK, 12 March 2019 – REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.
12 March 2019
REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
BELTSVILLE, MD. — REPROCELL Inc. and Fox Chase, Ltd., a member of the Fox Chase Cancer Center family of organizations, have formed a joint venture to begin operations of multi-site biosample repository facilities globally. The new Delaware-based joint venture company, Biorepository LLC, will act as a hub to manage its global subsidiaries, and its first subsidiary will be established in India in March.
28 February 2019
Appointment of New Distributor in China
The REPROCELL group has signed a non-exclusive distributorship agreement with RUITAI Biotechnology (Shanghai) Ltd to distribute REPROCELL’s products in China.
1 February 2019
The importance of internships for life science students
If you are a science student nearing the end of your university program, developing your professional network in order to land a good job is a daunting task. In this video, Zara Puckrin and Karen Bingham talk about Zara's experience interning at REPROCELL's Glasgow research lab and the benefits of internships for university students.
19 October 2018 • Life Sciences
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
Funding will be used to improve efficiency of induced pluripotent stem cell production
10 October 2018
REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER
REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan; hereinafter referred to as “GenAhead”). GenAhead is a venture company established by a team of experts in genetic modification technology. Since April 2018, REPROCELL has had a strategic investment in GenAhead.
9 October 2018
How paid internships can benefit life science students
How can industry inspire the next generation of life science professionals? In this post, summer intern Zara Puckrin describes the challenges faced by today’s graduates and explains how REPROCELL have helped her to bridge the gap between university and work.
13 September 2018 • Life Sciences
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
San Diego, CA, USA – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the Clinical Trial Notification (“CTN”), submitted by their Japan partner, REPROCELL, to the Japan Pharmaceuticals and Medical Device Agency (“PMDA”) for a Stemchymal® SCA Phase II clinical trial for Polyglutamine Spinocerebellar Ataxia (“PolyQ SCA”) has been approved. This is another key milestone for Steminent’s international Stemchymal® SCA Phase II clinical development program with trials now moving ahead in Taiwan, US, and Japan.
1 August 2018
Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services
REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.
21 June 2018
REPROCELL’s footprint extends to serve life sciences in India
REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
13 June 2018
Acquisition of BioServe Biotechnologies India Pvt. Ltd.
REPROCELL announces that it has acquired all the shares of BioServe Biotechnologies India Pvt. Ltd., (Hyderabad, India hereinafter referred to as “BioServe India”) from Cancer Genetics Inc. (USA). Bioserve India now becomes a subsidiary of REPROCELL.
26 April 2018
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.
18 April 2018
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
REPROCELL Europe Ltd was pleased to receive a visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017.
6 April 2018
REPROCELL’s David Bunton addresses the Scottish Parliament
On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance. He was also joined by:
• Dr Diane Harbison, CEO, of Stratified Medicine Scotland
• Claire Mack, CEO, of Scottish Renewables
• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK
21 March 2018
Patient-derived tumor organoids recapitulate clinical treatments
The pharmaceutical industry suffers from very high rates of clinical failure, because preclinical predictions of efficacy often fail to realize a clinical benefit. In part, this can be attributed to an over-reliance on animal models of efficacy, which often do not fully predict human responses to drugs.
Two areas where very few predictive models are available is inflammatory bowel disease (IBD)—which includes ulcerative colitis and Crohn’s disease—and gastrointestinal cancer—specifically cancer of the small intestine and the colon. REPROCELL has set out to solve these challenges by developing new preclinical tests based on human tissues, which we will explore in this article.
14 March 2018 • Drug Discovery
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
The SMi Group’s conference on 3D Cell Culture will be held on 21-22 February 2018.The venue is the Copthorne Tara Hotel in Kensington, London, UK.
Find out more at www.3d-CellCulture.com
REPROCELL Europe’s CSO Professor Stefan Przyborski will chair the first day of the conference.
24 January 2018
Formation of human tissue to improve drug testing and reduce animal research
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, was in Durham University (UK) News.
19 January 2018
REPROCELL Launches New Global Website
Regional companies and brands are integrated into one comprehensive English website demonstrating synergies of REPROCELL’s unique portfolio.
15 January 2018
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
New Cell Therapies for Central Nervous System Diseases Using IPSC-Derived Products
29 November 2017
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.
8 November 2017
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
27 September 2017
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
This following video is from Nicola Sturgeon, First Minister of Scotland's YouTube channel:
10 August 2017
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
New headquarters strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland. Press release 10th August 2017.
10 August 2017
REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India
Joint Venture Provides Quality Source of Clinically Annotated Tissue Specimens from Vast Indian Population
24 May 2017
REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
Alliance Provides Wider Access to Oncology Biospecimens to Accelerate Discovery and Translational Studies
13 April 2017
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer using techniques such as 3D models, PDX systems and precision-cut tumour slices. Chaired by Professor Gareth Thomas of the University of Southampton, presentations were delivered from, among others, Professor Will Shu and Dr Nick Lesley, who described developments in 3D bioprinting of tumours, and Dr Phil Quinlan of the UKCRC Tissue Directory.
3 March 2017
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
REPROCELL Inc. (Japan)’s CEO Dr Chikafumi Yokoyama had the honour of meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government, during her visit to the Scottish Enterprise Tokyo office, today (14 February 2017).
14 February 2017
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
Scotland’s Life Sciences Dinner was held on 2nd February 2017 at the National Museum of Scotland. The event was attended by CEO and Chairman of REPROCELL Inc, Dr Chikafumi Yokoyama, as well as senior management members of REPROCELL Europe Ltd, to join and celebrate the outstanding achievements of the Life Sciences sector in Scotland over the past year amongst over 800 guests.
7 February 2017
Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)
The SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb) will be chaired by REPROCELL Europe’s chief scientific officer (CSO), Professor Stefan Przyborski. He will also be giving the first lecture in the conference.
13 January 2017
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
REPROCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as the formation of said contract on the same day.
22 November 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.
16 November 2016
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
- Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
- Representative: CEO Chikafumi Yokoyama
- Inquiries: CFO Daisuke Usui (TEL.045-475-3887)
Today, REPROCELL Inc. (“REPROCELL”) has entered into a partnership with Steminent Biotherapeutics Inc. (“Steminent”) to develop and commercialize Steminent’s allogeneic stem cell therapy product, Stemchymal, in Japan. This announcement is in response to the acceptance of the agreement from the board committee on the event date.
11 November 2016
REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex
REPROCELL Europe has won the Corporate Vision Technology Innovation Award 2016 for Alvetex technology for 3D cell culture.
16 September 2016
Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting
ReproCELL Europe Ltd’s Chief Scientific Officer Prof Stefan Przyborski is giving a public lecture on “Scaffold Cell Culture Technology for Generation of In Vivo-like Tissue Models” at the British Biophysical Society 2016 Biennial Meeting 6th-8th July, University of Liverpool, Liverpool, UK.
6 July 2016
REPROCELL Europe’s (formerly Reinnervate’s) CSO Prof Stefan Przyborski to give an Alvetex Seminar at the University of Oxford, 24 May 2016
Professor Stefan Przyborski, Chief Scientific Officer of REPROCELL Europe (formerly Reinnervate), is to give a seminar on Alvetex next week, 24th May 2016.
20 May 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
13 May 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.
21 April 2016
Reinnervate Ltd wins Corporate Vision’s 2015 Technology Innovator Award for Alvetex
We are pleased to announce that Reinnervate Ltd has been awarded Corporate Vision’s 2015 Technology Innovator Award for Alvetex 3D cell culture. Alvetex has been awarded the title, “Most Advanced 3D Cell Technology.”
22 March 2016
Alvetex in Space
While the first British ESA astronaut Tim Peake is currently on the International Space Station (ISS) and is about to make his first spacewalk, now is a good time to mention again that Reinnervate’s flagship product, Alvetex® Scaffold, has been used as part of a BBSRC-funded project on the ISS in recent months.
14 January 2016
REPROCELL acquires Biopta to expand its drug discovery services
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of December 2015 and is aimed at strengthening REPROCELL’s pharmaceutical industry-targeted drug discovery services. The acquisition will also see an immediate investment to expand Biopta’s range of contract research services. Biopta, which will continue to operate from its headquarters in Glasgow, aims to grow its workforce to 30 over the next three years and Biopta’s management views the synergies within the REPROCELL Group of companies as key to its growth ambitions.
25 November 2015
Biopta co-authors research in the European Respiratory Journal
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society. This abstract describes the biological mechanisms by which a novel chemokine antagonist, AXP1275, impacts lung inflammation through its action at the CCR3-muscarinic M3 receptor heterodimer. The disease relevance of such biological complexity can only be truly demonstrated in fresh human tissue, in an environment where the receptor and pathway interaction occurs naturally.
18 November 2015
Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters
Notice concerning the publication of a paper concerning “3D culture model construction of mouse neurons” from a company in our group in the international neuroscience journal ‘Neuroscience Letters’
- Company: REPROCELL,Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: email@example.com
We are writing to inform you that a paper on the topic of “3D culture model construction of mouse neurons”, written by a company pertaining to our group, Reinnervate (UK) [now REPROCELL Europe], along with other contributors including Durham University (UK), who are engaged in cutting-edge research in the field of biotechnology, has recently been published in the ‘Neuroscience Letters’, a leading international journal.
18 November 2015
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
- Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: firstname.lastname@example.org
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.
16 November 2015
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
- Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: email@example.com
We are pleased to announce that a research report on “3D Skin Model Construction,” submitted by our corporate group member Reinnervate (Great Britain), pioneering biotechnology research center Durham University (Great Britain) and others, has been published in the scientific journal “Molecular Cancer Therapeutics,” a journal with global authority on cancer treatment.
19 October 2015
Joint Announcement with Ajinomoto Co., Inc. Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells
- Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: firstname.lastname@example.org
Joint Announcement with Ajinomoto Co., Inc.
24 September 2015
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
- Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
- Representative: Chikafumi Yokoyama, PhD
- Contact: email@example.com
We are pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.
8 September 2015
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
Announcement: REPROCELL’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income
- Company: REPROCELL, Inc.
- Representative: President and Representative Director Shuji Yokoyama (Company code: 4978)
- Point of contact: Business Management Director Daigo Obita (Telephone: 045-475-3887)
We would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).
14 August 2015
Announcement of Award for Prototype Development of a Liver Cell Kit
Announcement: FY 2014-2015 Grant (Additional) for Manufacturing, Commerce, and Service Innovation Has Been Awarded to “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem Cells for Applications in Drug Discovery”
1 July 2015
Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
NEW PRODUCT ANNOUNCEMENT: Stemgent StemRNA™-SR Reprogramming Kit
We are pleased to announce that Stemgent Inc. (Cambridge, MA), a REPROCELL Group Company (Yokohama, Japan – JASDAQ: 4978) has launched its new Stemgent StemRNA™-SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type.
30 June 2015
REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells
We are pleased to announce that our company has entered into an exclusive distribution and licensing agreement with Keio University regarding the myocardial cells originating from disease type iPS cells (derived from patients with hypertrophic cardiomyopathy).
4 June 2015
Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).
Sedgefield, UK. April 2015 – Market leading 3D cell culture company Reinnervate Ltd, part of the ReproCELL group, today announced that a rocket carrying its Alvetex® Scaffold technology blasted into Space this week. Alvetex will be used in experiments on board the International Space Station (ISS).
20 April 2015
New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system
A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells. The cells formed spontaneously active, functional neuronal networks which were not seen in an otherwise comparable 2D culture system. The 3D neural networks responded reproducibly to pharmacological treatments revealing functional glutamatergic synapses. Further imaging analysis revealed a neuronal and glial population, where markers of maturity were apparent in the former. Microrarray analysis of the cultures of the 3D and 2D neuronal cultures showed substantial differences in the gene expression profile of genes coding for neuronal function, extracellular matrix and cytoskeleton.
5 March 2015
RSC book publication: Human-based systems for translational research
Biopta's CEO publishes a review of functional human tissue assays in a new book entitled "Human-based systems for translational research", edited by Dr Robert Coleman and published by the Royal Society of Chemistry.
2 February 2015
Biopta and Proteon publish new research in Journal of Cardiovascular Pharmacology
A new paper in the Journal of Cardiovascular Pharmacology describes a potential treatment for atherosclerosis. Proteon Therapeutics, Waltham, MA, has developed a recombinant pancreatic elastase that was tested for its ability to dilate atherosclerotic human arteries, ethically obtained from patients with peripheral artery disease and set up at Biopta's human tissue research facility in Scotland.
13 January 2015
Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca
Scientists at AstraZeneca in the UK have compared the activity of a diverse compound set in 2D and 3D cell cultures using Alvetex® Scaffold 384 well plates in an automated Oncology HTS (High Throughput Screening) setting.
8 October 2014
REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)
YOKOHAMA, Japan — REPROCELL (JASDAQ:4978) announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. This acquisition allows the REPROCELL Group to expand the product lineups of its iPS Cell Business and establish technical advantages, promoting great differentiation.
9 September 2014
Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA)
Location: REPROCELL Inc. (Yokohama, Japan)
Date: August 5, 2014
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of Reinnervate Ltd. (UK), one of the leading companies in the field of 3D cell culture. REPROCELL intends to combine its iPSC-derived cells with the Alvetex range of 3D cell culture products to produce and sell next-generation tools for drug toxicity testing, neuro-science and cancer research.
5 August 2014
Scottish company creates first searchable database of human pharmacological responses in functional intact tissues
Biopta Ltd, the human tissue-based contract research organisation, today announced a major development in discovery research with the launch of the first catalog of assays based on human functional tissues. The catalogue serves to provide the scientific community with ready access to assays that improve the prediction of safety, absorption and efficacy of drug candidates in humans.
25 February 2014
Launch of Reinnervate Perfusion System for 3D cell culture
Reinnervate today announced the launch of a low-cost, simple system for combining 3D cell culture with dynamic circulation and perfusion of media.
5 February 2014
Biopta collaborates with Merck to investigate in vivo cardiac effects
In a recent collaboration with Merck, Biopta conducted human functional tissue experiments to investigate the mechanisms underlying two anti-arrhythmic drugs. Hemodynamic effects are often noted as adverse events with the use of antiarrhythmic drugs, including those used for the treatment of atrial fibrillation. To read a paper which explores the intrinsic vasorelaxant and inotropic effects of vernakalant and flecainide in isolated human subcutaneous resistance artery and in ventricular trabecular muscle preparations click the following link:
13 November 2013
Reinnervate Ltd partners with Oncotest and SBH Sciences on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture
Sedgefield, UK. November 2013 – 3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO’s to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.
4 November 2013
Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies
Sedgefield, UK. September 2013 – Specialist 3D cell culture company Reinnervate Ltd today announced that it is entering into a collaboration with leading stem cell company Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
19 September 2013
Prof. Stefan Przyborski to participate at the XCellR8 Human Primary Cell Culture course, 7 November 2013
Reinnervate’s CSO, Professor Stefan Przyborski, will be participating at the XCellR8 Human Primary Cell Culture course, which will be held on 7-8 November 2013 at their new premises in the Sci-Tech Daresbury Innovation Centre, UK.
22 August 2013
Alvetex 3D cell culture scaffolds chosen by investigators at Massachusetts General Hospital for study of bone loss during space flight
Planning 3D Osteocyte cell culture experiments on 2014 International Space Station (ISS) mission
Sedgefield, UK. August 2013 – Market leading 3D cell culture company Reinnervate Ltd today announced that its Alvetex® Scaffold system has been chosen by a group at Massachusetts General Hospital for the first ever 3D osteocytic cell culture experiments in microgravity.
31 July 2013
Scottish SMEs Announce Collaboration with Universities, Industry and NHS in Establishment of a £20m Stratified Medicine Scotland Innovation Centre
Today Scotland’s First Minister Alex Salmond announced the creation of a £20M Stratified Medicine Scotland Innovation Centre (SMS-IC), at the new South Glasgow Hospitals Campus. This is one of three innovation centres to be funded and signals commitment to the Scottish life sciences sector. Predicting in advance which groups of patients will respond to a particular therapy is termed stratified medicine (or personalised medicine). It has sometimes been summarised as providing “the right therapy, for the right patient, in the right dose, at the right time”.
23 April 2013
3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex® Scaffold 3D cell culture technology
Sedgefield, UK. 07th January 2013 – Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has entered into a co-marketing agreement with the pre-clinical Oncology CRO Oncotest GmbH.
7 January 2013
3D cell culture firm Reinnervate announces the release of Alvetex®Scaffold 96 well plates for high throughput 3D cell-based assays
Sedgefield, UK. November 2012 – Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has launched and commenced shipments of Alvetex® Scaffold 96 well plates to customers.
14 December 2012
Medicyte GmbH and Reinnervate Ltd to collaborate on development of next generation predictive 3D cell toxicity assays
Heidelberg, Germany and Sedgefield, UK. 9th July 2012 – Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte(inventors of the upcyte® technology) and Reinnervate (market leaders in the growing field of 3D cell culture) said they will work together to combine their upcyte® and Alvetex® Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.
9 July 2012
Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd
Sedgefield, UK. June 2012 – Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd has been recognised with a top award from the Royal Society of Chemistry.
27 June 2012
Reinnervate and Tecan to develop automated 3D cell culture solutions for improved cellular assays
Sedgefield, UK and Männedorf, Switzerland. 7 June 2012. Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture, based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex® Scaffold 3D cell culturing technology.
17 June 2012
Reinnervate Ltd and Roslin Cellab announce plans to collaborate
Sedgefield, UK. April 2012. Reinnervate Ltd and Roslin Cellab, two leading UK companies in the fields of 3D cell culture and stem cell biology, today announced that they will join forces to develop protocols for the three dimensional growth of human Embryonic Stem Cells (hESCs).
30 April 2012
Reinnervate Ltd announce Kirkstall Ltd collaboration
Reinnervate (inventors of Alvetex® Scaffold) and Kirkstall (developers of the Quasi-Vivo® system) today announced that they will collaborate to bring next-generation three dimensional (3D) cell culture products to market in 2012. The two UK companies are world leaders in the development of cell culture systems that bridge the current gap between 2D in vitro cell culture and animal models.
30 March 2012
Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®
Sedgefield, UK. November 2011. Reinnervate (Sedgefield, UK) and Mirus Bio (Madison, USA) today announced a commercial agreement to launch a new range of products for the transfection of cells cultured in 3D.
16 November 2011
Alvetex® voted one of most technologically significant new research products by R&D magazine
Sedgefield, UK. 23rd June 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.
27 June 2011
Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine
Sedgefield, UK. 1st December 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of The Scientist magazine’s“Top 10 Life Science Innovations of 2010”.
6 December 2010
Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture
Sedgefield, UK. 22nd November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is very pleased to announce today the first commercial launch of Alvetex®, its breakthrough 3D cell culture technology.
22 November 2010
Reinnervate completes expansion into new purpose-built facility at NETPark
Sedgefield, UK. 16th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK. The move to the circa 10,000 square foot facility has enabled Reinnervate to begin commercial production of its Alvetex® 3D cell culture technology in readiness for its planned 4Q 2010 launch. Pictures of the new facility are available upon request.
17 November 2010
Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells
The potency of Reinnervate’s ec23® to enhance neuronal differentiation when added to cell culture growth media has been demonstrated in a paper accepted for publication in the next issue of Journal of Neuroscience Methods.1
28 September 2010
Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells
Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold optimised for 3D hepatocyte culture. Enhanced 3D in vitro models of liver tissues are anticipated to be of great importance to academic and industrial investigators for basic research and testing the function and toxicity of new pharmaceuticals.
28 September 2010
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP). The Company joins a group of over 35 organisations from across Europe actively involved in developing technologies for in vitro testing with the aim of replacing, reducing and refining animal testing.
14 September 2010
Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex
Sedgefield, UK. 27th May 2010. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, today announced that it had successfully raised £1.8 million in new equity funding to complete the development of and support the commercialisation of its Alvetex® 3D cell culture technology platform. The funds were raised from Newcastle-based NorthStar Ventures, which committed £500,000 with the remaining amount coming from the Business Investment Group (BiG), management and private investors.
27 May 2010